OAN reporter fired from FDA appointment is still at FDA, flouting rules

FDA review

The drug Trump and Miller were referring to as “like a cure” for COVID-19 is a cocktail of monoclonal antibodies made by Regeneron Pharmaceuticals. Trump was given the drug swiftly after he revealed October 2 that he had tested positive for the novel coronavirus, SARS-CoV-2, which causes COVID-19. The cocktail is still in clinical trials and has little data on its effectiveness.

Regeneron issued a press release September 29 stating that high doses of its antibody cocktail appeared to cause levels of SARS-CoV-2 to decrease more quickly in infected patients who were not hospitalized for their infection. But the full data has not been published or released, and the information available so far is not enough to determine if the treatment is effective.

Trump received the experimental treatment as part of a “compassionate use” request and is among fewer than 10 people who have received the drug this way, according to the company.

On October 7—the same day as Miller’s promotional tweet—Regeneron requested that the FDA issue an Emergency Use Authorization for the cocktail, which would open access to the drugs outside of clinical trials. Regeneron said that it has enough doses for about 50,000 patients and expects to make 300,000 doses total available within the next few months.

The FDA is still considering the request.

Related posts

Why ‘huh’ is the only universal human word


Microsoft Flight Simulator in VR: A turbulent start for wide-open skies


Amazon cuts off Parler’s Web hosting following Apple, Google bans


Explaining foam within the absence of cleaning soap: It’s a rigidity gradient


Apple earnings present robust iPad and Mac gross sales can’t make up for the iPhone


Creator or Creature? A Nightmare Wakes dramatizes the birth of Frankenstein


Leave a Comment